中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I

文献类型：期刊论文

作者Zhang, Wan-li1,3; Li, Na4; Shen, Qiang3; Fan, Men1; Guo, Xiao-dong2; Zhang, Xiong-wen1; Zhang, Zhou4; Liu, Xuan3
刊名ACTA PHARMACOLOGICA SINICA
出版日期2020-02-01
卷号41期号:2页码:237-248
关键词cancer cachexia traditional Chinese medicine spleen deficiency animal model muscle atrophy fat lipolysis atractylenolide I metabolic syndrome
ISSN号1671-4083
DOI10.1038/s41401-019-0275-z
通讯作者Zhang, Xiong-wen(xwzhang@sat.ecnu.edu.cn) ; Zhang, Zhou(zzhang@simm.ac.cn) ; Liu, Xuan(xuanliu@shutcm.edu.cn)
英文摘要Cancer cachexia is a multifactorial metabolic syndrome that affects similar to 50%-80% of cancer patients, and no effective therapy for cancer cachexia is presently available. In traditional Chinese medicine, a large portion of patients with cancer cachexia was diagnosed as spleen deficiency syndrome and treated with tonifying TCMs that produce clinic benefits. In this study we established a new animal model of spleen deficiency and cancer cachexia in mice and evaluated the therapeutic effects of atractylenolide I, an active component of tonifying TCM BaiZhu, in the mouse model. Cancer cachexia was induced in male BALB/c mice by inoculation of mouse C26 colon adenocarcinoma cells, whereas spleen deficiency syndrome was induced by treating the mice with spleen deficiency-inducing factors, including limited feeding, fatigue, and purging. The mouse model was characterized by both cachexia and spleen deficiency characteristics, including significant body weight loss, cancer growth, muscle atrophy, fat lipolysis, spleen, and thymus atrophy as compared with healthy control mice, cancer cachexia mice, and spleen deficiency mice. Oral administration of atractylenolide I (20 mg center dot kg(-1)per day, for 30 days) significantly ameliorated the reduction in body weight and atrophy of muscle, fat, spleen, and thymus in mice with spleen deficiency and cachexia. The established model of spleen deficiency and cancer cachexia might be useful in the future for screening possible anticachexia TCMs and clarifying their mechanisms.
WOS关键词TRADITIONAL CHINESE MEDICINE ; SKELETAL-MUSCLE ; GASTRIC-CANCER ; MICE BEARING ; TUMOR ; ATROPHY ; PATHOGENESIS ; ACTIVATION ; MECHANISMS ; CARCINOMA
资助项目National Natural Science Foundation of China[81873056] ; National Natural Science Foundation of China[81872496] ; Shanghai Science and Technology Innovation Action Program[15140904800] ; Open Project of the State Key Laboratory of Innovative Natural Medicine, and Traditional Chinese Medicine Injections[QFSKL2018006]
WOS研究方向Chemistry ; Pharmacology & Pharmacy
语种英语
WOS记录号WOS:000510769500011
出版者NATURE PUBLISHING GROUP
源URL[http://119.78.100.183/handle/2S10ELR8/281706]  
专题中国科学院上海药物研究所
通讯作者Zhang, Xiong-wen; Zhang, Zhou; Liu, Xuan
作者单位1.East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Mol Engn, Shanghai 200062, Peoples R China
2.Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Dept Oncol, Shanghai 200437, Peoples R China
3.Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Biomed Res, Shanghai 201203, Peoples R China
4.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Zhang, Wan-li,Li, Na,Shen, Qiang,et al. Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I[J]. ACTA PHARMACOLOGICA SINICA,2020,41(2):237-248.
APA Zhang, Wan-li.,Li, Na.,Shen, Qiang.,Fan, Men.,Guo, Xiao-dong.,...&Liu, Xuan.(2020).Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I.ACTA PHARMACOLOGICA SINICA,41(2),237-248.
MLA Zhang, Wan-li,et al."Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I".ACTA PHARMACOLOGICA SINICA 41.2(2020):237-248.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。